Serum levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand as markers of periprosthetic osteolysis

被引:38
|
作者
Granchi, Donatella
Pellacani, Andrea
Spina, Mauro
Cenni, Elisabetta
Savarino, Lucia Maria
Baldini, Nicola
Giunti, Armando
机构
[1] Ist Ortoped Rizzoli, Lab Pathophysiol Orthoped Implants, I-40136 Bologna, Italy
[2] Ist Ortoped Rizzoli, Orthoped & Traumatol Div 7, I-40136 Bologna, Italy
来源
关键词
D O I
10.2106/JBJS.E.01038
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Previous studies have suggested that the balance between receptor activator of nuclear factor-kappa B ligand (RANKL) and its decoy-receptor osteoprotegerin (OPG) in local tissue seems to play a crucial role in the loosening of the total hip replacement. The aim of this study was to evaluate whether the circulating levels of OPG and RANKL, as well as their ratio, could be different in patients with aseptic loosening compared with patients with stable implants. Methods: One hundred and twenty-eight subjects were recruited. They included thirty-nine patients with osteoarthritis who had not yet undergone total hip arthroplasty, thirty-three patients who had undergone total hip arthroplasty and had clinically and radiographically stable implants, thirty-six patients with aseptic loosening of total hip arthroplasty components, and twenty healthy volunteers. Serum levels of OPG and RANKL were measured with use of an immunoenzymatic method, and in each individual the OPG-to-RANKL ratio was calculated. Results: In every group, a significant correlation was detected between OPG concentration and age (r = 0.58, p < 0.0001), especially in individuals older than fifty years, while gender and underlying disease were not found to influence serum levels of the tested parameters. In comparison with the levels in healthy donors and patients with a stable total hip replacement, the serum levels of OPG were increased in the patients who had not yet had an arthroplasty, those with aseptic loosening of a total hip replacement, and those with a cemented total hip replacement. Moreover, the OPG serum level provided good diagnostic accuracy in detecting the implant failure. A correlation was found between the sum of the osteolytic areas seen radiographically around the femoral stem and the RANKL level (r = 0.38, p = 0.02) and the OPG-to-RANKL ratio (r = -0.29, p = 0.04). Conclusions: An increase in OPG levels may reflect a protective mechanism of the skeleton to compensate for the osteolytic activity that occurs in severe osteoarthritis and in aseptic loosening. Prospective studies are needed to determine whether serum OPG levels could be used as markers for monitoring the stability of the implant, as well as for predicting aseptic loosening.
引用
收藏
页码:1501 / 1509
页数:9
相关论文
共 50 条
  • [21] Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
    Trouvin, Anne-Priscille
    Goeb, Vincent
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 345 - 354
  • [22] Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?Osteoprotegerin (OPG) und Receptor Activator for Nuclear Factor kappaB Ligand (RANKL) Bestimmung im Serum: Sinn oder Unsinn?
    Doris Wagner
    Astrid Fahrleitner-Pammer
    Wiener Medizinische Wochenschrift, 2010, 160 (17-18) : 452 - 457
  • [23] The role of serum osteoprotegerin and receptor–activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery
    José A. Balsa
    Christian Lafuente
    Jesús M. Gómez-Martín
    Julio Galindo
    Roberto Peromingo
    Francisca García-Moreno
    Gloria Rodriguez-Velasco
    Javier Martínez-Botas
    Diego Gómez-Coronado
    Héctor F. Escobar-Morreale
    José I. Botella-Carretero
    Journal of Bone and Mineral Metabolism, 2016, 34 : 655 - 661
  • [24] Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand
    Wang, Qing-Ping
    Yang, Li
    Li, Xian-Ping
    Xie, Hui
    Liao, Er-Yuan
    Wang, Min
    Luo, Xiang-Hang
    BONE, 2012, 51 (03) : 515 - 523
  • [25] Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-κB ligand: the Tromsø Study
    L. Jørgensen
    A. Vik
    N. Emaus
    J. Brox
    J.-B. Hansen
    E. Mathiesen
    P. Vestergaard
    Osteoporosis International, 2010, 21 : 931 - 938
  • [26] Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-κB ligand: the Tromso Study
    Jorgensen, L.
    Vik, A.
    Emaus, N.
    Brox, J.
    Hansen, J. -B.
    Mathiesen, E.
    Vestergaard, P.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (06) : 931 - 938
  • [27] Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    ENDOCRINOLOGY, 2001, 142 (03) : 1290 - 1295
  • [28] Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues
    Liu, Wei
    Zhang, Xianlong
    MOLECULAR MEDICINE REPORTS, 2015, 11 (05) : 3212 - 3218
  • [29] Osteoprotegerin-receptor activator of nuclear factor-κB ligand ratio:: A new approach to osteoporosis treatment?
    Coetzee, M
    Kruger, MC
    SOUTHERN MEDICAL JOURNAL, 2004, 97 (05) : 506 - 511
  • [30] In vitro expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in cultured equine articular cells
    Byron, Christopher R.
    Barger, Anne M.
    Stewart, Allison A.
    Pondenis, Holly C.
    Fan, Timothy M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (06) : 615 - 622